A new daily pill, Obicetrapib, shows promise in lowering cholesterol and reducing heart attack risk. A Phase 3 trial at Monash University involving over 2,500 participants with heart disease or high cholesterol demonstrated a 32.6% reduction in LDL cholesterol and a 33.5% drop in Lp(a) after 12 weeks. While well-tolerated, further studies are needed to confirm long-term effects and efficacy across diverse populations. The findings, published in The New England Journal of Medicine, suggest Obicetrapib could be a valuable addition to existing heart disease treatments.

Prepared by Olivia Bennett and reviewed by editorial team.